Filing Details
Gain Therapeutics, Inc. (NASDAQ:GANX) filed a Form 8-K with the Securities and Exchange Commission on July 16, 2026, disclosing a material event.
8k filedNASDAQ:GANX
Gain Therapeutics, Inc. (GANX) Reports Material Event to SEC
Filing Details Gain Therapeutics, Inc. (NASDAQ:GANX) filed a Form 8-K with the Securities and Exchange Commission on July 16, 2026, disclosing a material event. Market Context…
Market Context
Gain Therapeutics, Inc.'s stock currently trades at $1.66 with a market capitalization of $148.5M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Gain Therapeutics, Inc.'s stock.
All SEC filings for Gain Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View GANX Stock Page
Frequently Asked Questions
Where can I read GANX's SEC filings?
Browse all filings on our GANX SEC filings page.
What types of SEC filings does Gain Therapeutics, Inc. file?
Public companies like Gain Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.